Compare · HUM vs ILMN
HUM vs ILMN
Side-by-side comparison of Humana Inc. (HUM) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HUM and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $45.67B, about 1.1x ILMN ($41.36B).
- Over the past year, HUM is up 57.3% and ILMN is up 194.7% - ILMN leads by 137.3 points.
- HUM has been more active in the news (4 items in the past 4 weeks vs 3 for ILMN).
- Both have 25 recent analyst ratings on file.
- Company
- Humana Inc.
- Illumina Inc.
- Price
- $401.61+0.87%
- $270.73+0.25%
- Market cap
- $45.67B
- $41.36B
- 1M return
- +2.32%
- +18.92%
- 1Y return
- +57.34%
- +194.68%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2000
- News (4w)
- 4
- 3
- Recent ratings
- 25
- 25
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest HUM
- Humana upgraded by Barclays with a new price target
- New Humana research finds association between pharmacy care coordination services and improved health outcomes for cancer patients
- Humana Community Day 2026 Generates 2.2 Million Meals and Community Investments Nationwide
- New Study Links Integrated Specialty Pharmacy Care to Faster Access and Lower Costs
- Chief Medical Officer Nundy Shantanu was granted 2,549 units of Humana Common (SEC Form 4)
- Humana Earns 2026 Great Place To Work Certification™ and PEOPLE Companies That Care® Recognition
- Humana Board Declares Payment of Quarterly Dividend to Stockholders
- Humana Foundation Names 2026 Scholarship Recipients
- Humana Inc. filed SEC Form 8-K: Regulation FD Disclosure
- New insider Nundy Shantanu claimed no ownership of stock in the company (SEC Form 3)
Latest ILMN
- Chief Legal Officer Coletti Julie Ann was granted 18,763 shares (SEC Form 4)
- SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 408 shares, decreasing direct ownership by 0.99% to 40,927 units (SEC Form 4)
- UBS resumed coverage on Illumina with a new price target
- Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600
- Director Meister Keith A. sold $57,199,201 worth of shares (263,560 units at $217.03) (SEC Form 4)
- The Market Just Told You Which Layer Of AI Biology It Is Paying For
- Director Meister Keith A. sold $85,241,664 worth of shares (375,941 units at $226.74) (SEC Form 4)
- Director Meister Keith A. sold $145,556,398 worth of shares (679,574 units at $214.19) (SEC Form 4)
- SVP, Strategy/Corp Development Wedel Christensen Jakob sold $197,840 worth of shares (1,033 units at $191.52), decreasing direct ownership by 7% to 14,023 units (SEC Form 4)
- SEC Form 8-K filed by Illumina Inc.